Study
| A Phase III, double-blind, placebo-controlled, multicenter, international Study (AEGEAN) |
| Resectable Stages IIA to IIIB Non-small Cell Lung Cancer |
| Perioperative Durvalumab + Chemotherapy (n=366) vs. chemotherapy (n=374) |
Efficacy
| pCR: 17.2% vs. 4.2% |
| mPR: 33% vs. 13% |
| ORR: 56.3% vs. 38.0% |
| mEFS: NR vs. 25.9 mos, HR:0.68 |
| 12 mos EFS: 73.4 % vs. 64.5% |
| 24 mos EFS: 63.3% vs. 52.4% |
Safety
| Grade3: Neutrophenia (9.7% vs. 10.8%), anemia (6.5 % vs. 6.5%) |
N Engl J Med 2023; 389:1672-1684
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
http://doi.org/10.1056/NEJMoa2304875
Reviewed by Elvin Chalabiyev, MD on Nov 20, 2023
